Dermapharm Holding Se · XETR:DMP
Dermapharm — Q1 2022 Earnings Presentation
14 slides from Dermapharm's earnings presentation, May 18, 2022
Slide 1: Interim Statement Q1
Dermapharm Holding so 9022
Slide 2: Consolidated Results at a Glance
CONSOLIDATED RESULTS AT A GLANCE Q1 2022 Q1 2021 Revenue EUR million 231.6 212.2 Adjusted EBITDA* EUR million 75.1 63.7 Adjusted EBITDA margin* % 32.4 30.0 Unadjusted EBITDA EUR million 71.3 62.8 Unadjusted EBITDA margin % 30.8 29.6 Operating result EUR million 58.1 51.8 Earnings before taxes EUR mi
Slide 3: Share Information
3 Share information Report on economic position Report on expected development Interim consolidated statements SHARE INFORMATION EUR The shares at a glance (XETRA) 95.00 High (3 November 2021) EUR 90.35 Low (20 December 2018) EUR 21.625 85.00 Closing price (13 May 2022) EUR 51.75 75.00 Trading volum
Slide 4: Report on Economic Position
4 Share information Report on economic position Report on expected development Interim consolidated statements REPORT ON ECONOMIC POSITION 1. Course of business Dermapharm Holding SE held its own in a turbulent economic This resulted in an adjusted EBITDA of EUR 69.4 million, Segment Parallel import
Slide 5: Revenue and earnings performance
5 Share information Report on economic position Report on expected development Interim consolidated statements 2. Revenue and earnings performance Revenue trend Earnings before interest, tax, depreciation and The adjusted consolidated EBITDA for the first three months of 2022 amounted to EUR 75.1
Slide 6: Performance of the segments
6 Share information Report on economic position Report on expected development Interim consolidated statements Performance of the segments Quarter-on-quarter revenue trend by segment Quarter-on-quarter EBITDA trend by segment EUR million EUR million 240 80 1.2 220 6.1 70 200 60.4 1.0 180 61.9 60 5.5
Slide 7: Reports on Expected Developments
7 Share information Report on economic position Report on expected development Interim consolidated statements REPORTS ON EXPECTED DEVELOPMENTS Based on a solid first quarter of 2022, Dermapharm is pleased to confirm its forecast for financial year 2022. Despite the lingering uncertainties due to th
Slide 8: Condensed Statement of Financial Position
8 Share information Report on economic position Report on expected development Interim consolidated statements INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS AT 31 MARCH 2022 Rounding differences may arise due to the different presentation of figures in EUR million in the economic report and EUR thous
Slide 9: Equity and liabilities
9 Share information Report on economic position Report on expected development Interim consolidated statements Equity and liabilities EUR thousand 31 March 2022 31 December 2021 Equity Issued capital 53,840 53,840 Capital reserves 100,790 100,790 Retained earnings 375,325 337,954 Other reserves 4,13
Slide 10: Condensed Statement of Comprehensive Income
10 Share information Report on economic position Report on expected development Interim consolidated statements CONDENSED STATEMENT OF COMPREHENSIVE INCOME EUR thousand Q1 2022 Q1 2021 Revenue 231,641 212,211 Change in inventories 4,215 5,847 Own work capitalised 4,082 3,495 Other operating income 3
Slide 11: Condensed Statement of Cash Flows
11 Share information Report on economic position Report on expected development Interim consolidated statements CONDENSED STATEMENT OF CASH FLOWS EUR thousand Q1 2022 Q1 2021 Profit or loss for the period 57,402 49,024 Depreciation, amortisation / (reversal of impairment) of fixed assets 12,538 11,2
Slide 12: Segment Reporting
12 Share information Report on economic position Report on expected development Interim consolidated statements SEGMENT REPORTING Branded pharmaceuticals Q1 2022 and other healthcare Reconciliation / Group EUR thousand products Herbal extracts Parallel import business holding company Group Revenue 1
Slide 13: Imprint
IMPRINT Publisher Concept, editing, layout and typesetting Dermapharm Holding SE Dermapharm Holding SE Lil-Dagover-Ring 7 Lil-Dagover-Ring 7 82031 Grünwald 82031 Grünwald Germany Germany Tel.: +49 (89) 6 41 86 – 0 Tel.: +49 (89) 6 41 86 – 0 E-Mail: ir@dermapharm.com E-Mail: ir@dermapharm.com https:/
Slide 14: Dermapharm Holding SE
Dermapharm Holding SE Lil-Dagover-Ring 7 82031 Grünwald Germany Phone: +49 (89) 6 41 86 – 0 E-Mail: ir@dermapharm.com https://ir.dermapharm.de